Literature DB >> 16446171

Evaluation of Brucella abortus DNA vaccine by expression of Cu-Zn superoxide dismutase antigen fused to IL-2.

Andrés González-Smith1, Ramesh Vemulapalli, Edilia Andrews, Angel Oñate.   

Abstract

The Cu-Zn superoxide dismutase (SOD) antigen of Brucella abortus was previously identified to be a T cell antigen which induces both proliferation of and gamma interferon (IFN-gamma) secretion by T cells from infected mice. In an earlier study, we demonstrated that intramuscular injection of mice with a plasmid DNA carrying the gene for SOD leads to the development of significant protection against B. abortus challenge. It has been reported that the antigen-specific immune responses generated by a DNA vaccine can be enhanced by co-delivery of certain cytokine genes. In this study, we evaluated the effect of delivering IL-2 on the efficacy of SOD DNA vaccine by generating a plasmid (pSecTag-SOD-IL2) that codes for a secretory fusion protein of SOD and IL-2. Another plasmid (pSecTag-SOD) that codes for only SOD as a secretory protein was used for comparison. BALB/c mice injected intramuscularly with pSecTag-SOD or pSecTag-SOD-IL2, but not the control plasmid pSecTag, developed SOD-specific antibody and T cell immune responses. Upon in vitro stimulation with recombinant SOD (rSOD) antigen, T cells from mice immunized with pSecTag-SOD-IL2, in comparison with those from mice immunized with pSecTag-SOD, exhibited a lower proliferation response but produced significantly higher concentrations of IFN-gamma. Both DNA vaccines, however, induced similar levels of SOD-specific antibodies and cytotoxic T cell response. Although mice immunized with pSecTag-SOD-IL2 showed increased resistance to challenge with B. abortus virulent strain 2308, this increase was not statistically significant from that of pSecTag-SOD vaccinated mice. These results suggest that a SOD DNA vaccine fused to IL2 did not improve protection efficacy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16446171     DOI: 10.1016/j.imbio.2005.09.004

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  9 in total

1.  Use of S-[2,3-bispalmitoyiloxy-(2R)-propyl]-R-cysteinyl-amido-monomethoxy polyethylene glycol as an adjuvant improved protective immunity associated with a DNA vaccine encoding Cu,Zn superoxide dismutase of Brucella abortus in mice.

Authors:  Angello Retamal-Díaz; Roberto Riquelme-Neira; Darwin Sáez; Alejandra Rivera; Pablo Fernández; Alex Cabrera; Carlos A Guzmán; Angel Oñate
Journal:  Clin Vaccine Immunol       Date:  2014-08-27

2.  Liposomal delivery of p-ialB and p-omp25 DNA vaccines improves immunogenicity but fails to provide full protection against B. melitensis challenge.

Authors:  Nicola J Commander; James M Brewer; Brendan W Wren; Stephen A Spencer; Alastair P Macmillan; Judith A Stack
Journal:  Genet Vaccines Ther       Date:  2010-07-16

Review 3.  Recent advances in Brucella abortus vaccines.

Authors:  Elaine M S Dorneles; Nammalwar Sriranganathan; Andrey P Lage
Journal:  Vet Res       Date:  2015-07-08       Impact factor: 3.683

4.  Meta-Analysis and Advancement of Brucellosis Vaccinology.

Authors:  Tatiane F Carvalho; João Paulo A Haddad; Tatiane A Paixão; Renato L Santos
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

5.  Proteomic and Antibody Profiles Reveal Antigenic Composition and Signatures of Bacterial Ghost Vaccine of Brucella abortus A19.

Authors:  Chuan-Yu He; Jiang-Hua Yang; Yin-Bo Ye; Hai-Long Zhao; Meng-Zhi Liu; Qi-Lin Yang; Bao-Shan Liu; Sun He; Ze-Liang Chen
Journal:  Front Immunol       Date:  2022-04-22       Impact factor: 8.786

Review 6.  Evaluation of Brucellosis Vaccines: A Comprehensive Review.

Authors:  Mohsen Heidary; Shirin Dashtbin; Roya Ghanavati; Marzie Mahdizade Ari; Narjess Bostanghadiri; Atieh Darbandi; Tahereh Navidifar; Malihe Talebi
Journal:  Front Vet Sci       Date:  2022-07-18

7.  Characterization of recombinant B. abortus strain RB51SOD toward understanding the uncorrelated innate and adaptive immune responses induced by RB51SOD compared to its parent vaccine strain RB51.

Authors:  Jianguo Zhu; Charles B Larson; Megan Ann Ramaker; Kimberly Quandt; Jered M Wendte; Kimberly P Ku; Fang Chen; George W Jourdian; Ramesh Vemulapalli; Gerhardt G Schurig; Yongqun He
Journal:  Front Cell Infect Microbiol       Date:  2011-11-25       Impact factor: 5.293

Review 8.  A history of the development of Brucella vaccines.

Authors:  Eric Daniel Avila-Calderón; Ahidé Lopez-Merino; Nammalwar Sriranganathan; Stephen M Boyle; Araceli Contreras-Rodríguez
Journal:  Biomed Res Int       Date:  2013-06-03       Impact factor: 3.411

9.  Immune response to dna vaccine expressing transferrin binding protein a gene of Pasteurella multocida.

Authors:  Satparkash Singh; Vijendra Pal Singh; Pawanjit Singh Cheema; Maninder Sandey; Rajeev Ranjan; Santosh Kumar Gupta; Bhaskar Sharma
Journal:  Braz J Microbiol       Date:  2011-06-01       Impact factor: 2.476

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.